) The long range objective of this proposal is to obtain a molecular and chemical description of both the wild type CFTR protein and those mutant forms that cause cystic fibrosis. Work during the first 4 years of this project resulted in some novel, exciting and definitive progress. Both putative nucleotide domains (NBF1 and NBF2) of CFTR were shown by direct methods to bind ATP and ADP; the major disease causing mutation deltaF508 was shown to induce a marked instability and cause partial unfolding within NBF1; and microcrystals of an NBF1 fusion protein were obtained. In more recent work, NBF1 was shown to catalyze ATPase activity, be phosphorylated by protein kinase A, and associate with the membrane. In addition, 3-dimensional models of both NBF1 and NBF2 based on x-ray structures of known ATPases have been constructed for the first time. Future work will focus on relating the ATP binding and hydrolytic functions of NBF1 to a) phosphorylation capacity, b) structure, c) membrane binding, d) capacity to interact with and be modulated by NBF2, and e) mutant forms that cause cystic fibrosis.
Specific aims are 5-fold and will be to: 1. Define those conditions which are optimal for supporting the ATP binding and ATP hydrolytic functions of NBF1 by carefully examining thereon both the effect of covalent phosphorylation and the effect of physiological anions and cations. 2. Identify, using site directed mutagenesis and a 3-dimensional model as a guide, those amino acids most critical for the ATP binding and ATP hydrolytic functions of NBF1, and the effect on these functions of disease causing mutations residing within this domain. 3. Elucidate the nature of the membrane binding interaction of NBF1, recently discovered in this laboratory, when the peptide segment G404-N432 preceding the domain is present. 4. Establish whether NBF2 exhibits the capacity to hydrolyze or only bind ATP, and the extent to which this domain in the absence or presence of the R domain interacts with NBF1 in a functionally important manner. 5. Vigorously continue ongoing experiments to obtain preparations of NBF1 suitable for 3-dimensional structural analysis. These studies are fundamental to understanding those structure-function relationships within both wild type CFTR and in mutant forms thereof which cause most cases of cystic fibrosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK043962-07
Application #
2770395
Study Section
Special Emphasis Panel (ZRG3-MEDB (02))
Program Officer
Mckeon, Catherine T
Project Start
1991-05-01
Project End
1999-11-30
Budget Start
1998-09-29
Budget End
1999-11-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Annereau, Jean Philippe; Ko, Young Hee; Pedersen, Peter L (2003) Cystic fibrosis transmembrane conductance regulator: the NBF1+R (nucleotide-binding fold 1 and regulatory domain) segment acting alone catalyses a Co2+/Mn2+/Mg2+-ATPase activity markedly inhibited by both Cd2+ and the transition-state analogue orthovanada Biochem J 371:451-62
Pedersen, Peter L (2002) Transport ATPases in biological systems and relationship to human disease: a brief overview. J Bioenerg Biomembr 34:327-32
Ko, Y H; Pedersen, P L (2001) Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease. J Bioenerg Biomembr 33:513-21
Massiah, M A; Ko, Y H; Pedersen, P L et al. (1999) Cystic fibrosis transmembrane conductance regulator: solution structures of peptides based on the Phe508 region, the most common site of disease-causing DeltaF508 mutation. Biochemistry 38:7453-61
Thomas, P J; Ko, Y H; Shenbagamurthi, P et al. (1995) Nucleotide domains in transport ATPases: structure-function and relationship to disease. Soc Gen Physiol Ser 50:17-28
Ko, Y H; Thomas, P J; Pedersen, P L (1994) The cystic fibrosis transmembrane conductance regulator. Nucleotide binding to a synthetic peptide segment from the second predicted nucleotide binding fold. J Biol Chem 269:14584-8
Thomas, P J; Pedersen, P L (1993) Effects of the delta F508 mutation on the structure, function, and folding of the first nucleotide-binding domain of CFTR. J Bioenerg Biomembr 25:11-9
Ko, Y H; Thomas, P J; Delannoy, M R et al. (1993) The cystic fibrosis transmembrane conductance regulator. Overexpression, purification, and characterization of wild type and delta F508 mutant forms of the first nucleotide binding fold in fusion with the maltose-binding protein. J Biol Chem 268:24330-8
Thomas, P J; Ko, Y H; Pedersen, P L (1992) Altered protein folding may be the molecular basis of most cases of cystic fibrosis. FEBS Lett 312:7-9
Thomas, P J; Shenbagamurthi, P; Sondek, J et al. (1992) The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. J Biol Chem 267:5727-30